Department of Community Medicine, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian 16150, Malaysia.
Unit of Biostatistics and Research Methodology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian 16150, Malaysia.
Int J Environ Res Public Health. 2021 May 14;18(10):5237. doi: 10.3390/ijerph18105237.
Bladder cancer ranked ninth of principal male cancer in Malaysia. This study aimed to evaluate the clinical characteristics and survival of bladder cancer patients in Malaysia.
A retrospective cohort study was conducted by obtaining records in the Malaysian National Cancer Registry. Patients aged 15 years old and above with diagnosis date between 2007 and 2011 were included. Death was updated until 31 December 2016. Five-year observed survival and median survival time were determined by the life table method and Kaplan-Meier estimate method.
Among 1828 cases, the mean (SD) age of diagnosis was 64.9 (12.5) years. The patients were predominantly men (78.7%), Malay ethnicity (49.4%) and transitional cell carcinoma (78.2%). Only 14.8% of patients were at stage I. The overall five-year observed survival and median survival time was 36.9% (95% CI: 34.6, 39.1) and 27.3 months (95% CI: 23.6, 31.0). The highest five-year observed survival recorded at stage I (67.6%, 95% CI: 62.0, 73.3) and markedly worsen at stage II (34.3%, 95% CI: 27.9, 40.8), III (25.7%, 95% CI: 18.7, 32.6) and IV (12.2%, 95% CI: 8.1, 16.3).
Survival of bladder cancer patients in Malaysia was lower with advancing stage. The cancer control programme should be enhanced to improve survival.
膀胱癌在马来西亚男性主要癌症中排名第九。本研究旨在评估马来西亚膀胱癌患者的临床特征和生存情况。
通过获取马来西亚国家癌症登记处的记录，进行了一项回顾性队列研究。纳入 2007 年至 2011 年间诊断年龄在 15 岁及以上的患者。死亡数据更新至 2016 年 12 月 31 日。通过寿命表法和 Kaplan-Meier 估计法确定 5 年观察生存率和中位生存时间。
在 1828 例患者中，诊断时的平均（SD）年龄为 64.9（12.5）岁。患者主要为男性（78.7%）、马来人（49.4%）和移行细胞癌（78.2%）。仅 14.8%的患者处于 I 期。总体 5 年观察生存率和中位生存时间分别为 36.9%（95%CI：34.6，39.1）和 27.3 个月（95%CI：23.6，31.0）。I 期的 5 年观察生存率最高（67.6%，95%CI：62.0，73.3），而在 II 期（34.3%，95%CI：27.9，40.8）、III 期（25.7%，95%CI：18.7，32.6）和 IV 期（12.2%，95%CI：8.1，16.3）则显著恶化。
马来西亚膀胱癌患者的生存率随分期进展而降低。应加强癌症控制计划以提高生存率。
